Abstract
Familial hypercholesterolemia (FH) is an inherited metabolic disorder characterized by high levels of plasma low density lipoproteins (LDL) and an increased risk of premature atherosclerosis and coronary heart disease. LDL receptor (LDLr) deficiency is the most prevalent cause of FH. Therefore, hepatocyte-directed LDLr gene transfer constitutes an important strategy for the treatment of this monogenetic disease. Nowadays, homozygous FH patients are treated with lipid-lowering drugs complemented by plasma or LDL apheresis. Liver transplantation can restore metabolism of apolipoprotein B containing lipoproteins, but requires lifelong immunosuppression to prevent organ rejection. Recently, significant progress in gene transfer technology has encouraged investigators to further develop LDLr gene transfer approaches for the treatment of FH. In experimental animal models of FH, LDLr overexpression following viral vector-based gene transfer has been shown to be associated with long-term stable correction of hyperlipidemia, with attenuation of atherosclerosis progression, and in certain cases even with lesion regression. The first part of this review provides a thorough overview of familial hypercholesterolemia including its diagnosis, lipoprotein metabolism, and current management. In the second part, we critically review experimental LDLr gene transfer studies demonstrating the progress that has been made from the initial proof of principle studies to recent investigations showing dramatic regression of atherosclerosis in experimental models.
Keywords: Familial hypercholesterolemia, gene therapy, low density lipoprotein receptor gene transfer, atherosclerosis, dyslipidemia, cardiac ischemia, acetylcoenzyme A synthetase, C-reactive protein, organ rejection, hepatocytes
Current Pharmaceutical Design
Title: Gene Therapy for Familial Hypercholesterolemia
Volume: 17 Issue: 24
Author(s): Eline Van Craeyveld, Frank Jacobs, Stephanie C. Gordts and Bart De Geest
Affiliation:
Keywords: Familial hypercholesterolemia, gene therapy, low density lipoprotein receptor gene transfer, atherosclerosis, dyslipidemia, cardiac ischemia, acetylcoenzyme A synthetase, C-reactive protein, organ rejection, hepatocytes
Abstract: Familial hypercholesterolemia (FH) is an inherited metabolic disorder characterized by high levels of plasma low density lipoproteins (LDL) and an increased risk of premature atherosclerosis and coronary heart disease. LDL receptor (LDLr) deficiency is the most prevalent cause of FH. Therefore, hepatocyte-directed LDLr gene transfer constitutes an important strategy for the treatment of this monogenetic disease. Nowadays, homozygous FH patients are treated with lipid-lowering drugs complemented by plasma or LDL apheresis. Liver transplantation can restore metabolism of apolipoprotein B containing lipoproteins, but requires lifelong immunosuppression to prevent organ rejection. Recently, significant progress in gene transfer technology has encouraged investigators to further develop LDLr gene transfer approaches for the treatment of FH. In experimental animal models of FH, LDLr overexpression following viral vector-based gene transfer has been shown to be associated with long-term stable correction of hyperlipidemia, with attenuation of atherosclerosis progression, and in certain cases even with lesion regression. The first part of this review provides a thorough overview of familial hypercholesterolemia including its diagnosis, lipoprotein metabolism, and current management. In the second part, we critically review experimental LDLr gene transfer studies demonstrating the progress that has been made from the initial proof of principle studies to recent investigations showing dramatic regression of atherosclerosis in experimental models.
Export Options
About this article
Cite this article as:
Van Craeyveld Eline, Jacobs Frank, C. Gordts Stephanie and De Geest Bart, Gene Therapy for Familial Hypercholesterolemia, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247550
DOI https://dx.doi.org/10.2174/138161211797247550 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Social Determinants of Childhood Obesity: Beyond Individual Choices
Current Pediatric Reviews Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide
Current Medicinal Chemistry Stress and Physical Inactivity: Two Explosive Ingredients for the Heart in COVID-19 Pandemic Times
Current Cardiology Reviews Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Mild Systemic Inflammation has a Neuroprotective Effect After Stroke in Rats
Current Neurovascular Research Effect of Intravitreal Injection of Aflibercept on Cardiovascular Risk Parameters in Patients with Neovascular Age-Related Macular Degeneration
Current Reviews in Clinical and Experimental Pharmacology Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Periodontitis, Endothelial Dysfunction and Atherosclerosis
Vascular Disease Prevention (Discontinued) Genetic Determinants of Severe Respiratory Syncytial Virus Infection and Post-Bronchiolitis Wheeze: A Systematic Review
Current Respiratory Medicine Reviews Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Molecular Pharmacological Approaches to Effects of Capsaicinoids and of Classical Antisecretory Drugs on Gastric Basal Acid Secretion and on Indomethacin-Induced Gastric Mucosal Damage in Human Healthy Subjects (Mini Review)
Current Pharmaceutical Design Dietary Technologies to Optimize Healing from Injury-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Episcleritis and Scleritis in Rheumatic Disease
Current Rheumatology Reviews A Critical Review of Bioactive Food Components, and of their Functional Mechanisms, Biological Effects and Health Outcomes
Current Pharmaceutical Design MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art
Current Medicinal Chemistry